The Steep Drop In Clover Health Stock Sets up an Entry Opportunity_老虎社区_美港股上老虎

The Steep Drop In Clover Health Stock Sets up an Entry Opportunity

InvestorPlace2021-12-29

I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Ice1234
·2021-12-29
👍🏼
回复
2
举报
poworb
·2021-12-29
T
回复
4
举报
收起
- Ice1234:
  👍🏼
  2021-12-29
  回复
  举报
- Wolala:
  v
  2021-12-29
  回复
  举报
- poworb:
  r
  2021-12-29
  回复
  举报
Kave
·2021-12-29
[Happy] [Happy]
回复
7
举报
收起
- Ninja16:
  😄
  2021-12-29
  回复
  举报
ycwoo
·2021-12-29
Ok
回复
6
举报
收起
- Kave:
  [Happy] [Happy]
  2021-12-29
  回复
  举报
jcwe
·2021-12-29
ok
回复
5
举报
收起
- ycwoo:
  ok
  2021-12-29
  回复
  举报
- jcwe:
  ok
  2021-12-29
  回复
  举报
Samwich
·2021-12-29
Ok
回复
5
举报
收起
- Samwich:
  Oo
  2021-12-29
  回复
  举报
Windtalker78
·2021-12-29
A stock on downward spiral since early 2021. Good luck.
回复
4
举报
收起
- NatYong:
  [OK]
  2021-12-29
  回复
  举报
- Mystery746:
  [smile]
  2021-12-29
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1173363100?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-29 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173363100","market":"us","top_or_hot":-1,"title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","media":"InvestorPlace","content":"<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","article_id":"1173363100","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","pubTimestamp":1640779518,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"三叶草健康股的急剧下跌为进入提供了机会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLOV":0.9},"content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":696771837,"gmtCreate":1640783568555,"gmtModify":1640783568730,"author":{"id":"3576662504844996","authorId":"3576662504844996","name":"Ice1234","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576662504844996","authorIdStr":"3576662504844996"},"htmlText":"👍🏼","listText":"👍🏼","text":"👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696771837","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":696746522,"gmtCreate":1640781296837,"gmtModify":1640781334316,"author":{"id":"3585789495202228","authorId":"3585789495202228","name":"poworb","avatar":"https://static.tigerbbs.com/a0c7f322470251fc4ca32b11d191c166","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585789495202228","authorIdStr":"3585789495202228"},"htmlText":"T","listText":"T","text":"T","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/696746522","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7135268,"gmtCreate":1640783591677,"gmtModify":1640783591774,"authorId":3576662504844996,"author":{"id":3576662504844996,"idStr":"3576662504844996","authorId":3576662504844996,"name":"Ice1234","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696746522,"type":1,"supId":7135209,"prevId":0,"content":"👍🏼","text":"👍🏼","html":"👍🏼"},{"id":7135209,"gmtCreate":1640782887350,"gmtModify":1640782887384,"authorId":3582878170475225,"author":{"id":3582878170475225,"idStr":"3582878170475225","authorId":3582878170475225,"name":"Wolala","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696746522,"type":1,"supId":0,"prevId":0,"content":"v","text":"v","html":"v"},{"id":7135086,"gmtCreate":1640781301818,"gmtModify":1640781301847,"authorId":3585789495202228,"author":{"id":3585789495202228,"idStr":"3585789495202228","authorId":3585789495202228,"name":"poworb","avatar":"https://static.tigerbbs.com/a0c7f322470251fc4ca32b11d191c166","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696746522,"type":1,"supId":0,"prevId":0,"content":"<u>r</u>","text":"<u>r</u>","html":"<u>r</u>"}],"langContent":"CN"},{"id":696743153,"gmtCreate":1640780304679,"gmtModify":1640780304911,"author":{"id":"4090112981805970","authorId":"4090112981805970","name":"Kave","avatar":"https://static.tigerbbs.com/7928a22910f1e6651ac7f9dbf8e9c369","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090112981805970","authorIdStr":"4090112981805970"},"htmlText":"[Happy]&nbsp;[Happy]&nbsp;","listText":"[Happy]&nbsp;[Happy]&nbsp;","text":"[Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696743153","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7135036,"gmtCreate":1640780513586,"gmtModify":1640780513680,"authorId":3585825658773327,"author":{"id":3585825658773327,"idStr":"3585825658773327","authorId":3585825658773327,"name":"Ninja16","avatar":"https://static.tigerbbs.com/548f908bc09db96d20c354e9f7fcd86d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696743153,"type":1,"supId":0,"prevId":0,"content":"😄","text":"😄","html":"😄"}],"langContent":"CN"},{"id":696749257,"gmtCreate":1640780143459,"gmtModify":1640780173795,"author":{"id":"3565146699964497","authorId":"3565146699964497","name":"ycwoo","avatar":"https://static.tigerbbs.com/637be28a03f575af22b76a60dad1181b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3565146699964497","authorIdStr":"3565146699964497"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696749257","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7135021,"gmtCreate":1640780296378,"gmtModify":1640780296489,"authorId":4090112981805970,"author":{"id":4090112981805970,"idStr":"4090112981805970","authorId":4090112981805970,"name":"Kave","avatar":"https://static.tigerbbs.com/7928a22910f1e6651ac7f9dbf8e9c369","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696749257,"type":1,"supId":0,"prevId":0,"content":"[Happy] [Happy]","text":"[Happy] [Happy]","html":"[Happy] [Happy]"}],"langContent":"CN"},{"id":696749382,"gmtCreate":1640780111479,"gmtModify":1640780170694,"author":{"id":"3554894364783188","authorId":"3554894364783188","name":"jcwe","avatar":"https://static.tigerbbs.com/cc943a4e0949068fc7783ded47745212","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3554894364783188","authorIdStr":"3554894364783188"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696749382","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7135014,"gmtCreate":1640780137626,"gmtModify":1640780137738,"authorId":3565146699964497,"author":{"id":3565146699964497,"idStr":"3565146699964497","authorId":3565146699964497,"name":"ycwoo","avatar":"https://static.tigerbbs.com/637be28a03f575af22b76a60dad1181b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696749382,"type":1,"supId":7135013,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":7135013,"gmtCreate":1640780115674,"gmtModify":1640780115703,"authorId":3554894364783188,"author":{"id":3554894364783188,"idStr":"3554894364783188","authorId":3554894364783188,"name":"jcwe","avatar":"https://static.tigerbbs.com/cc943a4e0949068fc7783ded47745212","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696749382,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":696740070,"gmtCreate":1640779967609,"gmtModify":1640779967834,"author":{"id":"3575000650579772","authorId":"3575000650579772","name":"Samwich","avatar":"https://static.tigerbbs.com/333bbe08da61ec501a2da43a65e31462","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575000650579772","authorIdStr":"3575000650579772"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696740070","repostId":1173363100,"repostType":4,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7134991,"gmtCreate":1640779973816,"gmtModify":1640779973850,"authorId":3575000650579772,"author":{"id":3575000650579772,"idStr":"3575000650579772","authorId":3575000650579772,"name":"Samwich","avatar":"https://static.tigerbbs.com/333bbe08da61ec501a2da43a65e31462","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696740070,"type":1,"supId":0,"prevId":0,"content":"Oo","text":"Oo","html":"Oo"}],"langContent":"CN"},{"id":696757561,"gmtCreate":1640779853883,"gmtModify":1640779854644,"author":{"id":"3579431961273157","authorId":"3579431961273157","name":"Windtalker78","avatar":"https://static.tigerbbs.com/0bf69a5ab416d33d0b16be20ef91c642","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3579431961273157","authorIdStr":"3579431961273157"},"htmlText":"A stock on downward spiral since early 2021. Good luck.","listText":"A stock on downward spiral since early 2021. Good luck.","text":"A stock on downward spiral since early 2021. Good luck.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696757561","repostId":1173363100,"repostType":2,"repost":{"id":"1173363100","pubTimestamp":1640779518,"share":"https://www.laohu8.com/m/news/1173363100?lang=&edition=full","pubTime":"2021-12-29 20:05","market":"us","language":"en","title":"The Steep Drop In Clover Health Stock Sets up an Entry Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=1173363100","media":"InvestorPlace","summary":"Investors who are patient and want to take on some risk should find CLOV stock interesting","content":"<html><head></head><body><p>I am bullish on <b>Clover Health Investments</b> (NASDAQ:<b>CLOV</b>). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.</p><p>CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.</p><p>Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.</p><p>Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.</p><p>The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.</p><p><b>Q3 Earnings Show an Interesting Contrast</b></p><p>Revenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.</p><p>However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.</p><p>Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.</p><p>The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.</p><p>The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.</p><p><b>AI Solution for the Future</b></p><p>With Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.</p><p>Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by <b>Hindenburg Research</b> earlier this year. However, the physicians allegedly involved are not employees of Clover.</p><p>Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.</p><p><b>CLOV Stock Remains High Risk</b></p><p>In a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.</p><p>The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.</p><p>The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Steep Drop In Clover Health Stock Sets up an Entry Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Steep Drop In Clover Health Stock Sets up an Entry Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 20:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/12/the-steep-drop-in-clover-health-stock-sets-up-an-entry-opportunity/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173363100","content_text":"I am bullish on Clover Health Investments (NASDAQ:CLOV). It hits all the right beats in our current digital economy. A Medicare Advantage health insurance enterprise offers doctors and medical professionals data-driven solutions. CLOV stock has fallen close to 50% during the last three months.CLOV stock traded close to $15 per share in early January, hit a wall, and then kept falling until May. By June the stock started to rebound thanks to Reddit’s masses.However, the sentiment is leveling off. As I write this, the Clover Health stock price sits at $3.97.Keep in mind thaat Clover Health is a classic meme stock. But now that it has fallen from its astronomical heights, the time to buy is approaching. The company’s been on a roll lately, with revenue and member count increasing in 2021. Meanwhile, it has a lot of cash on its books. It recently announced a public offering of Class A common stock that will pull in $300 million of gross proceeds that Clover has earmarked for corporate purposes, among other things.Absent an urgent need for cash, the decision to raise capital may irk investors. But this is a new company that is growing. It needs money to invest in operations and its product. It has enough cash to last for a year or two, depending on how fast expenses rise as the business grows. The end of Q3 saw CLOV with $588 million in its coffers. If you add the proceeds from the equity offering, they have an excellent cash position.The company has made remarkable progress in recent months, setting them on a path toward profitability. If you look for a healthcare company with a bright future, CLOV stock is a great bet.Q3 Earnings Show an Interesting ContrastRevenues for the third quarter came in at $427 million, up 153% a year ago. Clover’s membership continues to grow fast, which will bring increased cost efficiencies and contribute significantly towards net earnings. This is one of the key factors that drives up their stock price — higher numbers mean better profitability.However, the company is forecasting operating losses for its fiscal 2022. Investors who are patient and want to take on some risk will find CLOV stock interesting.Medicare-focused health insurance is an investment that could provide investors with good return potential as the aging population faces high medical costs. The Medicare Advantage Insurance sector is on fire, with total market value expected to more than double $590 billion by 2025 from $270 billion.The business model for CLOV is a bit quirky. But it’s effective in that customers stay loyal to the plan. Each package offers something different, and what works with one person may not work on another, making them difficult to switch.The cost of healthcare can be confusing for people. It’s not just about how much you have to pay each year. But also when and which drugs are covered by your insurance plan? And what if there is more than one type or amount that applies in certain situations — do I need an appointment at the doctor’s office first before getting tested elsewhere (e.g., hospital)? Every enrollee should choose a plan that minimizes their total out-of-pocket costs according to personal healthcare needs. Hence, Clover Health offers an attractive value proposition.AI Solution for the FutureWith Clover Assistant, managers can provide high-tech AI software that increases patient care outcomes and reduces costs. The five-minute survey program collects data from patients for diagnostic tests, which is then analyzed by the artificial intelligence system to find possible illnesses or ailments.Medical inflation is illegal,and the Department of Justice (DOJ) has investigated CLOV for it, as reported by Hindenburg Research earlier this year. However, the physicians allegedly involved are not employees of Clover.Clover Assistant is a game-changer for CLOV. It has helped the company significantly increase its productivity and profitability by cutting down on tedious tasks, paperwork, or other administrative work that takes up so much of an employee’s day-to-day routine. The innovative software can help physicians identify potential health risks they might have overlooked, benefiting patients’ quality of life and increasing payments through risk adjustment.CLOV Stock Remains High RiskIn a high-growth, competitive industry where many companies are vying for market share and consumers’ attention alike, there’s always a risk that you will struggle. But despite these risks, Clover has persevered — thanks in part to their innovative practices, which have drawn praise from experts across the country.The DOJ launched an investigation into certain aspects of its operations. However, things don’t look too bad. Forecasts call for continued net losses through 2022, yet investors should remain as the company keeps finding ways to compete beyond things like price cuts or advertising campaigns.The stock may yet again be on its way to new heights, as it has been for much of this year. This time around, investors should watch when Clover begins reporting some positive earnings quarters shortly — that could mean another boost ahead. However, this time, the rally will be sustainable.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7135076,"gmtCreate":1640781140187,"gmtModify":1640781140222,"authorId":3580207321438450,"author":{"id":3580207321438450,"idStr":"3580207321438450","authorId":3580207321438450,"name":"NatYong","avatar":"https://static.tigerbbs.com/62b1fa39b2974271d1c06e208f7b3571","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696757561,"type":1,"supId":0,"prevId":0,"content":"[OK]","text":"[OK]","html":"[OK]"},{"id":7135007,"gmtCreate":1640780072856,"gmtModify":1640780072892,"authorId":3578426177245991,"author":{"id":3578426177245991,"idStr":"3578426177245991","authorId":3578426177245991,"name":"Mystery746","avatar":"https://static.tigerbbs.com/61c18bcc189aa2aabbaee265d94ce48b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":696757561,"type":1,"supId":0,"prevId":0,"content":"[smile]","text":"[smile]","html":"[smile]"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":28,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}